A Brisbane company's experimental anti-inflammatory drug is being tested as a potential treatment in COVID-19 patients as part of trials sponsored by the US Government. The drug, IC14, is being administered to Americans admitted to hospital with COVID-19 as part of two separate studies - in people on ventilators admitted to intensive care units and in others before they are ill enough for the ICU. IC14 was invented in the US but developed over more than a decade by Brisbane company Implicit Bioscience after its Chief Scientific Officer and celebrated Queensland immunologist Ian Frazer recognised its potential.